MedPath

HOSPITAL SULTANAH BAHIYAH

🇲🇾Malaysia
Ownership
-
Established
2007-01-01
Employees
-
Market Cap
-
Website
http://hsbas.moh.gov.my/eng/

Clinical Trials

4

Active:0
Completed:2

Trial Phases

1 Phases

Not Applicable:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials

Not Applicable
2 (100.0%)

Comparison of HYBRID Versus Two-Stent Strategies in Unprotected True Left MAIN Bifurcation

Not Applicable
Not yet recruiting
Conditions
Unprotected Left Main Coronary Artery Disease
First Posted Date
2025-09-08
Last Posted Date
2025-09-08
Lead Sponsor
Hospital Sultanah Bahiyah
Target Recruit Count
1708
Registration Number
NCT07159737

Malaysian COVID-19 Anosmia Study (Phase 1) - A Nationwide Multicentre Cross-Sectional Study

Completed
Conditions
COVID-19
Dysgeusia
SARS-CoV Infection
Anosmia
First Posted Date
2020-05-15
Last Posted Date
2021-02-25
Lead Sponsor
Hospital Sultanah Bahiyah
Target Recruit Count
498
Registration Number
NCT04390165
Locations
🇲🇾

Hospital Enche' Besar Hajjah Khalsom, Kluang, Johor, Malaysia

🇲🇾

Hospital Sultanah Bahiyah, Alor Setar, Kedah, Malaysia

🇲🇾

Hospital Raja Perempuan Zainab II, Kota Bharu, Kelantan, Malaysia

and more 11 locations

Malaysian COVID-19 Anosmia Study (Phase 2) - A Nationwide Multicentre Case-Control Study

Conditions
SARS-CoV Infection
Dysgeusia
COVID-19
Anosmia
First Posted Date
2020-05-12
Last Posted Date
2021-02-25
Lead Sponsor
Hospital Sultanah Bahiyah
Target Recruit Count
60
Registration Number
NCT04384042
Locations
🇲🇾

Hospital Enche' Besar Hajjah Khalsom, Kluang, Johor, Malaysia

🇲🇾

Hospital Sultanah Bahiyah, Alor Setar, Kedah, Malaysia

🇲🇾

Hospital Raja Perempuan Zainab II, Kota Bharu, Kelantan, Malaysia

and more 11 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.